Why the study?
Pediatric heart failure management relies largely on extrapolated adult data despite distinct etiologies and clinical courses, leaving a void for newer drugs in the pediatric population.
Does Sacubitril/Valsartan improve outcomes in pediatric patients with heart failure?
Does Sacubitril/Valsartan improve outcomes in pediatric patients with heart failure?
Sacubitril/Valsartan provides a new, FDA-approved pharmacological strategy for pediatric heart failure, reducing reliance on extrapolated adult data.
Offers FDA-approved option for pediatric HF; leaves open full efficacy confirmation from completed PANORAMA HF trial.
Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Arya et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: